Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion
Q4 2024 Management View CEO Yvonne Greenstreet highlighted 2024 as a strong year with $1.6 billion in net product revenues, achieving the upper end of the revised guidance. She emphasized the positive ...
pharmaphorum5d
Alnylam hails vutrisiran data, but investors seem sceptical
Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...
Alnylam Pharmaceuticals' SWOT analysis: promising outlook for ATTR-CM stock
Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...
UPI News on MSN9d
U.S. Navy intercepted test drone with HELIOS directed-energy weapon
The U.S. Navy has developed a directed-energy weapon that can intercept unmanned drones and possibly cruise missiles while ...
New York Post10d
US Navy fires its high-powered laser weapon that could obliterate warships and drones, incredible photo shows
A jaw-dropping new photo shows the US Navy firing off a drone-destroying laser weapon — dubbed Helios — from one of its warships. The undated image, which was published in the US Center for ...